Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: Two case reports

International Journal of Urology

Volumn 13, Issue 9, 2006, Pages 1259-1261

  Noguchi, Kazumi ^a   Teranishi, Jun Ichi ^a   Uemura, Hiroji ^a   Fujikawa, Naoya ^a   Saito, Kazuo ^a   Murai, Tetsuo ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b International Goodwill Hospital   (Japan)

Author keywords

Antiandrogen withdrawal syndrome; Chemical complete response; Chlormadinone acetate; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; HORMONE RESISTANCE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; WITHDRAWAL SYNDROME;

AGED; ANDROGEN ANTAGONISTS; CHLORMADINONE ACETATE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL RATE;

EID: 33748781970     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01515.x     Document Type: Article

References (10)

1. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 1993; 149: 607-9.
2. Akakura K, Akimoto S, Furuya Y, Ito H. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur. Urol. 1998; 33: 567-71.
3. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies. Incidence and clinical significance. Drug Saf. 2000; 23: 381-90.
4. Hara T, Miyazaki J, Araki H et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003; 63: 149-53.
5. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 2004; 171: 679-83.
6. Nakamura N, Narukawa M, Asahi T et al. A case of diabetic ketoacidosis induced by chlormadinone acetate. J. Jpn Diab. Soc. 1998; 41: 923-8.
7. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 1491-8.
8. Noguchi K, Uemura H, Harada M et al. Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slowreleasing LH-RH agonist. Int. J. Clin. Oncol. 2001; 6: 29-33.
9. Ozono S, Okajima E, Yamaguchi A et al. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer. Jpn J. Clin. Oncol. 2000; 30: 389-96.
10. Eisenberger MA, Carducci MA. Chemotherapy for hormone-resistant prostate cancer. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell's Urology, 8th edn. Saunders, Philadelphia, 2002; 3209-26.